LYMPHOMA, FOLLICULAR
Clinical trials for LYMPHOMA, FOLLICULAR explained in plain language.
Never miss a new study
Get alerted when new LYMPHOMA, FOLLICULAR trials appear
Sign up with your email to follow new studies for LYMPHOMA, FOLLICULAR, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
By submitting, you agree to our Terms of use
-
Real-World safety check for lymphoma drug
Disease control OngoingThis study is monitoring the safety of the drug tazemetostat in real-world clinical practice. It involves 145 Japanese patients with relapsed or hard-to-treat follicular lymphoma who have a specific genetic mutation (EZH2). The main goal is to track side effects and see how well …
Matched conditions: LYMPHOMA, FOLLICULAR
Sponsor: Eisai Co., Ltd. • Aim: Disease control
Last updated Apr 01, 2026 14:43 UTC
-
Two-Pronged attack: new combo therapy targets blood cancer
Disease control OngoingThis study is testing a new combination of two drugs for people with follicular lymphoma who have not yet received any treatment. The goal is to see how well the drugs work together to shrink or eliminate the cancer. One drug helps the body's immune cells find and kill cancer cel…
Matched conditions: LYMPHOMA, FOLLICULAR
Phase: PHASE2 • Sponsor: Washington University School of Medicine • Aim: Disease control
Last updated Mar 30, 2026 14:34 UTC
-
New drug combo trial aims to control advanced lymphoma without chemotherapy
Disease control OngoingThis study is testing whether adding a new drug called golcadomide to the standard treatment rituximab works better for people newly diagnosed with advanced follicular lymphoma. It aims to see if this combination can help more patients achieve a complete response and control the …
Matched conditions: LYMPHOMA, FOLLICULAR
Phase: PHASE2 • Sponsor: Celgene • Aim: Disease control
Last updated Mar 23, 2026 15:14 UTC
-
New drug combo tested to keep lymphoma at bay
Disease control OngoingThis study is for people with follicular lymphoma that has come back or stopped responding to initial treatment. It tests whether adding a drug called lenalidomide to standard maintenance therapy (rituximab) helps keep the cancer in remission longer after patients receive a round…
Matched conditions: LYMPHOMA, FOLLICULAR
Phase: PHASE3 • Sponsor: Fondazione Italiana Linfomi - ETS • Aim: Disease control
Last updated Mar 18, 2026 18:25 UTC